Interferon: Hope or hindrance?

March 1, 2004

Washington - In a retrospective review of 135 patients diagnosed with a primary, thick melanoma (Breslow ? 4mm) and/or pathological evidence of regional nodal metastasis, further analysis shows significant differences between those who undergo adjuvant interferon alfa-2b (IFN_2b) therapy and those who decline, said Tracy L. Bialy, M.D., M.P.H.